TRANSLATIONAL ONCOLOGY- PROGRAM Raymond Bergan, MD, and Sara A. Courtneidge, PhD, Program Co-Leaders ABSTRACT Translational Oncology (TO) is a multi-disciplinary program within the Knight Cancer Institute whose mission is to improve treatments, outcomes, and quality of life for people with cancer by advancing translational science. Members have transformed the field of translational cancer research and continue to lead by pursuing two integrated research themes: 1) validation of high value therapeutic targets, and 2) assessing the feasibility and efficacy of therapeutically targeting these pathways through impactful clinical investigations. Target validation is focused on intrinsic molecular cancer abnormalities, pathways that lead to invasion and metastases, interactions of cancer cells with the microenvironment, mechanisms of resistance to current therapies, and preclinical evaluation or development of novel agents targeting these pathways. Projects in the second theme focus on the development of drugs targeting tumor intrinsic molecular abnormalities, the tumor microenvironment, and immunotherapeutics, along with studies designed to understand how best to use these agents, who responds, why resistance occurs and means to circumvent resistance. The program is co-led by Raymond Bergan, MD, a molecular pharmacologist whose research focuses on targeted therapy across the spectrum of carcinogenesis, and Sara A. Courtneidge, PhD, a translational scientist whose research focuses on invadopodia and the microenvironment. The TO Program is comprised of 52 members from 14 Departments at OHSU. Between July 2011 and March 2016, TO members produced 623 cancer-relevant publications, of which 23% represented intra- programmatic, 25% inter-programmatic and 59% represented inter-institutional collaborative interactions. In 2015, a total of 2,019 individuals were entered on clinical studies, 700 of them interventional, 481 therapeutic. Total funding for the program is $27,170,631, peer-reviewed funding is $10,359,011, with $3,010,767 or 29% from NCI. Other cancer-relevant funding includes prostate and pancreatic Stand Up To Cancer Dream Team grants, several cancer clinical trials consortia, and a Leukemia & Lymphoma Society-funded program called Beat AML. In the current funding cycle, TO investigators had crucial roles in driving changes in FDA-approvals for 9 different agents for indications linked to improved survival in 12 cancers.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oregon Health and Science University
United States
Zip Code
Hulett, Tyler W; Jensen, Shawn M; Wilmarth, Phillip A et al. (2018) Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination. J Immunother Cancer 6:27
Vranka, Janice A; Staverosky, Julia A; Reddy, Ashok P et al. (2018) Biomechanical Rigidity and Quantitative Proteomics Analysis of Segmental Regions of the Trabecular Meshwork at Physiologic and Elevated Pressures. Invest Ophthalmol Vis Sci 59:246-259
Lane, Ryan S; Lund, Amanda W (2018) Non-hematopoietic Control of Peripheral Tissue T Cell Responses: Implications for Solid Tumors. Front Immunol 9:2662
Tyner, Jeffrey W; Tognon, Cristina E; Bottomly, Daniel et al. (2018) Functional genomic landscape of acute myeloid leukaemia. Nature 562:526-531
Risom, Tyler; Langer, Ellen M; Chapman, Margaret P et al. (2018) Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. Nat Commun 9:3815
Minnier, Jessica; Pennock, Nathan D; Guo, Qiuchen et al. (2018) RNA-Seq and Expression Arrays: Selection Guidelines for Genome-Wide Expression Profiling. Methods Mol Biol 1783:7-33
Su, Yulong; Pelz, Carl; Huang, Tao et al. (2018) Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals. Genes Dev 32:1398-1419
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Krey, Jocelyn F; Scheffer, Deborah I; Choi, Dongseok et al. (2018) Mass spectrometry quantitation of proteins from small pools of developing auditory and vestibular cells. Sci Data 5:180128
Rozanov, Dmitri V; Rozanov, Nikita D; Chiotti, Kami E et al. (2018) MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection. J Proteomics 176:13-23

Showing the most recent 10 out of 277 publications